

SPONSORED ABSTRACTS





ABSTRACT # TITLE SESSION

HODGKIN LYMPHOMA

ABSTRACT 7000

ABSTRACT

7053

Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study

Seven-year overall survival analysis from ECHELON-1

untreated stage III/IV classical Hodgkin lymphoma

study of A+AVD versus ABVD in patients with previously

ORAL PRESENTATIONHematologic Malignancies—
Lymphoma and Chronic

N es—

Lymphocytic Leukemia Saturday, June 1, 2024 3:00–6:00 PM CDT Location: S100bc

POSTER PRESENTATION

Hematologic Malignancies— Lymphoma and Chronic Lymphocytic Leukemia

Monday, June 3, 2024 9:00 AM-12:00 PM CDT

Location: Hall A



METASTATIC COLORECTAL CANCER (mCRC)

ABSTRACT 3507 Acquired gene alteration patterns and post-progression survival: PARADIGM study analysis

ORAL PRESENTATION



ral: PARADIGM study analysis

Gastrointestinal Cancer:
Colorectal and Anal
Sunday, June 2, 2024
8:00-11:00 AM CDT

Location: Arie Crown Theater

ABSTRACT 3579 Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2

POSTER PRESENTATION

Gastrointestinal Cancer-Colorectal and Anal Saturday, June 1, 2024



1:30-4:30 PM CDT Location: Hall A

NON-SMALL CELL LUNG CANCER (NSCLC)

<u>ABSTRACT</u> <u>11107</u> Feasibility and utilization of electronic patientreported outcome measures for lung cancer in routine clinical care POSTER PRESENTATION

Quality Care/Health Services Research

Monday, June 3, 2024 9:00 AM-12:00 PM CDT

Location: Hall A



LEUKEMIAS

ABSTRACT 6501 Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC

ORAL POSTER PRESENTATION



Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant

Friday, May 31, 2024 2:45-5:45 PM CDT Location: S100bc



Hematologic Malignancies— Leukemia, Myelodysplastic Syndromes, and Allotransplant

Monday, June 3, 2024 9:00 AM-12:00 PM CDT Location: Hall A



<u>6533</u>

ABSTRACT

In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL

VV-MEDMAT-104858, May 2024

TAKEDA and the TAKEDA logo are registered trademarks of Takeda Pharmaceutical Company Limited.

CERTAIN OF THESE ABSTRACTS MAY RELATE TO DRUGS AND/OR USES THAT ARE INVESTIGATIONAL,
AND FOR WHICH SAFETY AND EFFICACY HAVE NOT YET BEEN ESTABLISHED. THIS IS NO GUARANTEE
THAT SUCH DRUGS AND/OR USES WILL BE APPROVED.






ABSTRACT # TITLE SESSION

PIPELINE

ABSTRACT TPS2684

A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3 ϵ Conditional Bispecific Redirected Activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors



Immunotherapy

ABSTRACT

2543

Updated results from first-in-human Phase 1 doseescalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors

Location: Hall A POSTER PRESENTATION

POSTER PRESENTATION

Developmental Therapeutics—

Developmental Therapeutics— Immunotherapy

Saturday, June 1, 2024 9:00 AM-12:00 PM CDT

Location: Hall A





For more information, please see ASCO online program.



